The estimated Net Worth of John Johnson is at least $924 millier dollars as of 1 September 2024. Mr. Johnson owns over 11,904 units of Strongbridge Biopharma plc stock worth over $58,032 and over the last 11 years he sold SBBP stock worth over $72,410. In addition, he makes $793,125 as Chief Executive Officer at Strongbridge Biopharma plc.
Sign up
Mr. Johnson SBBP stock SEC Form 4 insiders trading
John has made over 5 trades of the Strongbridge Biopharma plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,904 units of SBBP stock worth $23,808 on 1 September 2024.
The largest trade he's ever made was exercising 215,600 units of Strongbridge Biopharma plc stock on 18 March 2024 worth over $429,044. On average, John trades about 5,939 units every 39 days since 2014. As of 1 September 2024 he still owns at least 29,016 units of Strongbridge Biopharma plc stock.
You can see the complete history of Mr. Johnson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Johnson biography
John H. Johnson serves as Chief Executive Officer of the Company. Mr. Johnson has served as a director of the Company since March 2015. He served as Chairman of the Board from March 2015 until November 2019 and Executive Chairman from November 2019 until July 2, 2020. Mr. Johnson recently served as Chief Executive Officer and a board member of Melinta Pharmaceuticals, Inc. through September 2019, having served as interim Chief Executive Officer since October 2018. Mr. Johnson is also a member of the board of directors of Verastem, Inc. (also known as Verastem Oncology). From January 2012 until August 2014, Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012, he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011, Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company’s Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008, and served on ImClone’s board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc.
What is the salary of John Johnson?
As the Chief Executive Officer of Strongbridge Biopharma plc, the total compensation of John Johnson at Strongbridge Biopharma plc is $793,125. There are 2 executives at Strongbridge Biopharma plc getting paid more, with Frederic Cohen having the highest compensation of $1,093,830.
How old is John Johnson?
John Johnson is 62, he's been the Chief Executive Officer of Strongbridge Biopharma plc since 2020. There are 2 older and 7 younger executives at Strongbridge Biopharma plc. The oldest executive at Strongbridge Biopharma plc is David Gill, 65, who is the Independent Director.
What's John Johnson's mailing address?
John's mailing address filed with the SEC is C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA, FL, 32615.
Insiders trading at Strongbridge Biopharma plc
Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over $0 worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth $8,846,818 . The most active insiders traders include Associates, L.L.C.Caxton Co..., Garheng Kong et Jeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of $593,478. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth $17,040.
What does Strongbridge Biopharma plc do?
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
What does Strongbridge Biopharma plc's logo look like?
Complete history of Mr. Johnson stock trades at AVEO Pharmaceuticals Inc, Axogen, Portola Pharmaceuticals, Strongbridge Biopharma plc, Verastem Inc et Xeris Biopharma Inc
Strongbridge Biopharma plc executives and stock owners
Strongbridge Biopharma plc executives and other stock owners filed with the SEC include:
-
Frederic Cohen,
Chief Medical Officer -
Robert Lutz,
Chief Financial Officer -
John Johnson,
Chief Executive Officer -
Marten Steen,
Independent Director -
Garheng Kong,
Lead Independent Director -
Richard Kollender,
Chief Operating Officer -
Hilde Steineger,
Independent Director -
Jeffrey Sherman,
Independent Director -
David Gill,
Independent Director -
Stephen Long,
Secretary, Chief Legal Officer -
Scott Wilhoit,
Chief Commercial Officer -
A Brian Davis,
Chief Financial Officer -
Matthew Pauls,
President & CEO -
Fredric J. Cohen,
Chief Medical Officer -
Associates, L.L.C.Caxton Co...,